Serogroup B Neisseria meningitidis MenB is the cause of an acute potentially severe infection known as invasive meningococcal disease IMD with two peaks in disease incidence occurring among adolescents and young adults to years of age Bexsero is the first genome-derived vaccine against MenB and it has recently been approved in countries worldwide Neisserial adhesin A NadA a meningococcal trimeric autotransporter adhesin TAA that acts in adhesion to and invasion of host epithelial cells is one of the three protein antigens included in Bexsero The main aim of this work was to obtain detailed insights into the structure of NadA
... More
|Related Solutions: Rock Imager®
Serogroup B Neisseria meningitidis (MenB) is the cause of an acute, potentially severe infection, known as invasive meningococcal disease (IMD) with two peaks in disease incidence occurring among adolescents and young adults 16 to 21 years of age. Bexsero is the first genome-derived vaccine against MenB, and it has recently been approved in >35 countries worldwide. Neisserial adhesin A (NadA), a meningococcal trimeric autotransporter adhesin (TAA) that acts in adhesion to, and invasion of, host epithelial cells, is one of the three protein antigens included in Bexsero. The main aim of this work was to obtain detailed insights into the structure of NadA variant 3 (NadAv3), the vaccine variant, and into the molecular mechanisms governing its transcriptional regulation by NadR (Neisseria adhesin A Regulator). The amount of NadA exposed on the meningococcal surface influences the antibody-mediated serum bactericidal response measured in vitro, which in turn correlates with protection in immunized subjects. A deep understanding of nadA expression is therefore important, otherwise the contribution of NadA to vaccine-induced protection against meningococcal disease may be underestimated. The abundance of surface-exposed NadA is regulated by the ligand-responsive transcriptional repressor NadR. The functional, biochemical and high-resolution structural characterization of NadR is presented in the first part of the thesis (Part One). These studies provide detailed insights into how small molecule ligands, such as hydroxyphenylacetate derivatives, found in relevant host niches, modulate the structure and activity of NadR, by ‘conformational selection’ of inactive forms. These findings shed light on the regulation of a key virulence factor and vaccine antigen of this important human pathogen. In the second part of the thesis (Part Two), strategies involving both protein engineering and crystal manipulation to increase the likelihood of solving the crystal structure of NadAv3 are described. The first approach was the rational design of new constructs of NadAv3, based on the recently solved crystal structure of a close sequence variant (NadAv5). Then, a comprehensive set of biochemical, biophysical and structural techniques were applied to investigate all the generated NadAv3 constructs, aiming to faithfully represent its natural trimeric status, essential for reliable structural, functional and epitope mapping studies. The well-characterized trimeric NadAv3 constructs represented a set of high quality reagents which were validated as probes for functional studies and as a platform for continued attempts for protein crystallization. Mutagenesis studies and screenings to identify a new crystal form of NadAv3 were performed to improve crystal quality, ultimately allowing the collection of several high quality X-ray diffraction data sets; structure determination is ongoing. The atomic resolution structure of NadAv3 will help to understand its biological role as both an adhesin and a vaccine antigen. For example, the high resolution structure will enable epitope mapping studies using human antibodies and thus permit a 7 deeper understanding of the molecular determinants of antibody binding and protective epitopes. In addition, it will help to understand the molecular basis of host-pathogen interactions mediated by specific human cell receptors.
Less
|Related Solutions: Rock Imager®